Immune Targeting Systems (ITS) Ltd unveils first influenza vaccine targeting all human, avian & swine influenza viral strains
Immune Targeting Systems (ITS) announced it has developed the world's first fully synthetic Influenza vaccine which targets all Human, Bird and Swine influenza strains. By targeting highly conserved components within all these viral strains it means that no matter what bird flu virus ultimately emerged to cause a pandemic this vaccine would have the potential to provide protection from severe disease, as well as reduce mortality rates. This fully synthetic vaccine can be produced in hundreds of millions of doses without the complications associated current influenza vaccine production methods. The company has also developed an HIV/AIDS vaccine targeting all major viral strains responsible for this worsening global pandemic and a Hepatitis-C vaccine targeting the difficult to treat genotype-1, which is also the most globally prevalent strain.
The company has drawn its inspiration from Mother Nature and the decades of vaccine failures and short comings associated with these mutating viruses. ITS uses computer based prediction methods linked to publicly available viral sequence databases to identify highly conserved pieces from all these viruses which are also frequently targeted by the immune system. These are then attached to the company's proprietary vaccine delivery vector to create fully synthetic V-peptide vaccines. When delivered as a vaccine these are expected to generate specific killer T-cell immune responses in humans capable of attacking the virus's Achilles heel to control it. The virus is expected to be less able to mutate and escape from the immune system's control.
Other news from the department research and development
